610 related articles for article (PubMed ID: 27402157)
1. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
6. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
7. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
8. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
9. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
13. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
[TBL] [Abstract][Full Text] [Related]
15. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
16. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
17. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
18. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
Vieira ML; Zhao P; Berglund EG; Reynolds KS; Zhang L; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2012 Apr; 91(4):700-8. PubMed ID: 22398966
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
20. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
